These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23424313)

  • 1. Balancing drug and payer costs.
    Adams KT
    Biotechnol Healthc; 2005 Oct; 2(5):64. PubMed ID: 23424313
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors influencing third party payer costs for allogeneic BMT.
    Griffiths RI; Bass EB; Powe NR; Anderson GF; Goodman S; Wingard JR
    Bone Marrow Transplant; 1993 Jul; 12(1):43-8. PubMed ID: 8397032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.
    Frey S; Stargardt T; Schneider U; Schreyögg J
    Pharmacoeconomics; 2019 Aug; 37(8):1029-1039. PubMed ID: 30949989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital use, associated costs, and payer status for infants born with spina bifida.
    Radcliff E; Cassell CH; Tanner JP; Kirby RS; Watkins S; Correia J; Peterson C; Grosse SD
    Birth Defects Res A Clin Mol Teratol; 2012 Dec; 94(12):1044-53. PubMed ID: 23115108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate setting and hospital cost-containment: all-payer versus partial-payer approaches.
    Zuckerman S
    Health Serv Res; 1987 Aug; 22(3):307-26. PubMed ID: 3316123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic Nissen fundoplication (LNF) in a large healthcare system.
    Ayazi S; Zaidi AH; Zheng P; Chovanec K; Chowdhury N; Salvitti M; Newhams K; Levy J; Hoppo T; Jobe BA
    Surg Endosc; 2020 May; 34(5):2279-2286. PubMed ID: 31376004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National cost of trauma care by payer status.
    Velopulos CG; Enwerem NY; Obirieze A; Hui X; Hashmi ZG; Scott VK; Cornwell EE; Schneider EB; Haider AH
    J Surg Res; 2013 Sep; 184(1):444-9. PubMed ID: 23800441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reflections on the 20th anniversary of Taiwan's single-payer National Health Insurance System.
    Cheng TM
    Health Aff (Millwood); 2015 Mar; 34(3):502-10. PubMed ID: 25732502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Payer cost savings with endometrial ablation therapy.
    London R; Holzman M; Rubin D; Moffitt B
    Am J Manag Care; 1999 Jul; 5(7):889-97. PubMed ID: 10557409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of hospital performance under the partial-payer Medicare PPS and state all-payer rate-setting systems.
    Rosko MD
    Inquiry; 1989; 26(1):48-61. PubMed ID: 2523344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing patient value and payer cost in hematologic malignancies: can it be done?
    Allen PB; Flowers CR
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):123-126. PubMed ID: 29486601
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary payer status is associated with mortality and resource utilization for coronary artery bypass grafting.
    LaPar DJ; Stukenborg GJ; Guyer RA; Stone ML; Bhamidipati CM; Lau CL; Kron IL; Ailawadi G
    Circulation; 2012 Sep; 126(11 Suppl 1):S132-9. PubMed ID: 22965973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maryland's all-payer system: a delicate balancing act.
    Wagner K
    Healthc Financ Manage; 2011 Nov; 65(11):112-6. PubMed ID: 22128603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary payer status affects outcomes for cardiac valve operations.
    Lapar DJ; Bhamidipati CM; Walters DM; Stukenborg GJ; Lau CL; Kron IL; Ailawadi G
    J Am Coll Surg; 2011 May; 212(5):759-67. PubMed ID: 21398153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.
    Cheng JS; Lee MJ; Massicotte E; Ashman B; Gruenberg M; Pilcher LE; Skelly AC
    Spine (Phila Pa 1976); 2011 Oct; 36(21 Suppl):S144-63. PubMed ID: 21952186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between payer mix and costs, revenues and profitability: a cross-sectional study of Lebanese hospitals.
    Saleh S; Ammar W; Natafgi N; Mourad Y; Dimassi H; Harb H
    East Mediterr Health J; 2015 Sep; 21(6):381-8. PubMed ID: 26369996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single payer as a financing mechanism.
    Glied S
    J Health Polit Policy Law; 2009 Aug; 34(4):593-615. PubMed ID: 19633224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Payer costs in patients undergoing uterine artery embolization, hysterectomy, or myomectomy for treatment of uterine fibroids.
    Dembek CJ; Pelletier EM; Isaacson KB; Spies JB
    J Vasc Interv Radiol; 2007 Oct; 18(10):1207-13. PubMed ID: 17911509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.